- World rank, 2022–2025
- #10,931 of 28,054 · #20,949 all time
- Rank in China
- #1,958 of 3,058
- Research works
- 191 ▲ 178% vs 2013–17
- Citations
- 3.3k 17.3 per fractional work
- Top-10% rate
- 22.3% record average 16.5%
- Open access
- 52% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.9×. Every wedge is a field page.
- Immunology and Microbiology 6.9×
- Mathematics 4.0×
- Biochemistry, Genetics and Molecular Biology 3.5×
- Medicine 2.8×
- Pharmacology, Toxicology and Pharmaceutics 1.7×
- Chemistry 1.1×
- Economics, Econometrics and Finance 0.8×
- Dentistry 0.8×
- Decision Sciences 0.5×
- Nursing 0.3×
- Neuroscience 0.3×
- Engineering 0.3×
- Materials Science 0.3×
- Computer Science 0.3×
- Agricultural and Biological Sciences 0.2×
- Psychology 0.1×
- Physics and Astronomy 0.1×
- Environmental Science 0.1×
- Health Professions 0.1×
- Business, Management and Accounting 0.0×
- Social Sciences 0.0×
Who are the top researchers at BeiGene (China)?
Ranked on the composite score, Xiaomin Song, Wenfeng Gong and Lai Wang lead among researchers whose main affiliation is BeiGene (China).
- 1 Xiaomin Song China · #327,451 worldwide 166 citations · 29 works
- 2 Wenfeng Gong China · #712,429 worldwide 48 citations · 19 works
- 3 Lai Wang China · #931,139 worldwide 52 citations · 32 works
Which keywords describe research at BeiGene (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Rituximab, Tumor Microenvironment, Prognostic Factors, Lymphoma, Chemotherapy, Immune Checkpoint Blockade, PD-1 and PD-L1 and Therapeutic Targets.
- Treatment Guidelines
- EGFR Mutations
- Bayesian Methods
- Immunity
- Hodgkin's Lymphoma
- Molecular Profiling
- Endoscopic Resection
- Cancer Therapy
- Gene Expression
- Chimeric Antigen Receptor
- Fc Receptors
- Therapeutic Antibodies
- Glycosylation
- Monoclonal Antibodies
- Targeted Therapy
- Therapeutic Targets
- Chronic Lymphocytic Leukemia
- Immune Checkpoint Blockade
- Chemotherapy
- Tumor Microenvironment
- Rituximab
- Prognostic Factors
- Lymphoma
- PD-1 and PD-L1
- Genomic Aberrations
- Immunotherapy
- Cancer Immunotherapy
- Cancer
- PET Imaging
- Antibody Engineering
- CAR T Cells
- Tumor Regression
- Clinical Trials
- Classification
- Gene Expression Profiling
- Genetic Pathogenesis
- Neoadjuvant Therapy
- ALK Inhibitors
- Cell Death
- Survival Analysis
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Rituximab10▲ 67×2 topics
- Tumor Microenvironment9▲ 21×5 topics
- Prognostic Factors9▲ 21×8 topics
- Chemotherapy7▲ 10×14 topics
- Lymphoma7▲ 45×2 topics
- Immune Checkpoint Blockade7▲ 63×1 topic
- PD-1 and PD-L17▲ 63×1 topic
- Chronic Lymphocytic Leukemia7▲ 152×1 topic
- Genomic Aberrations7▲ 152×1 topic
- Therapeutic Targets7▲ 45×2 topics
- Immunotherapy6▲ 8.7×9 topics
- Targeted Therapy6▲ 28×4 topics
- Cancer Immunotherapy6▲ 38×3 topics
- Monoclonal Antibodies6▲ 65×3 topics
- Cancer6▲ 4.3×18 topics
- Glycosylation5▲ 49×3 topics
- PET Imaging5▲ 31×4 topics
- Therapeutic Antibodies5▲ 73×2 topics
- Antibody Engineering5▲ 85×1 topic
- Fc Receptors5▲ 85×1 topic
- CAR T Cells4▲ 55×1 topic
- Chimeric Antigen Receptor4▲ 55×1 topic
- Tumor Regression4▲ 37×2 topics
- Gene Expression4▲ 6.0×8 topics
- Clinical Trials4▲ 5.4×5 topics
- Cancer Therapy3▲ 6.1×11 topics
- Classification3▲ 7.4×2 topics
- Endoscopic Resection3▲ 35×2 topics
- Gene Expression Profiling3▲ 41×2 topics
- Molecular Profiling3▲ 34×2 topics
- Genetic Pathogenesis3▲ 61×1 topic
- Hodgkin's Lymphoma3▲ 61×1 topic
- Neoadjuvant Therapy3▲ 14×5 topics
- Immunity3▲ 7.1×6 topics
- ALK Inhibitors3▲ 44×1 topic
- Bayesian Methods3▲ 55×2 topics
- Cell Death3▲ 12×6 topics
- EGFR Mutations3▲ 44×1 topic
- Survival Analysis3▲ 10×7 topics
- Treatment Guidelines3▲ 13×2 topics
Which research topics does BeiGene (China) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 7 works
- 2 Chronic Lymphocytic Leukemia Research Genetics 7 works
- 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 5 works
- 4 CAR-T cell therapy research Oncology 4 works
- 5 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 3 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 7 Esophageal Cancer Research and Treatment Surgery 2 works
- 8 Statistical Methods in Clinical Trials Statistics and Probability 2 works
- 9 Immune Cell Function and Interaction Immunology 2 works
- 10 Cancer Genomics and Diagnostics Cancer Research 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has BeiGene (China)'s research output changed?
Output in 2018–2022 was 178% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Beijing
- Chinese Academy of Sciences
- Tsinghua University
- Peking University
- University of Chinese Academy of Sciences
- Beihang University
- Beijing Institute of Technology
- Chinese Academy of Medical Sciences & Peking Union Medical College
- North China Electric Power University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.